Observation of the Isospin-Violating Decay Ds∗+→Ds+π0D_s^{*+}\to D_s^+\pi^0

Using data collected with the CLEO~II detector, we have observed the isospin-violating decay $D_s^{*+}\to D_s^+\pi^0$. The decay rate for this mode, relative to the dominant radiative decay, is found to be $\Gamma(D_s^{*+}\to D_s^+\pi^0)/\Gamma(D_s^{*+}\to D_s^+\gamma)= 0.062^{+0.020}_{-0.018}\pm0.022$.Comment: 8 page uuencoded postscript file, also available through http://w4.lns.cornell.edu/public/CLN

Measurement of the Inclusive Semi-electronic D0D^0 Branching Fraction

Using the angular correlation between the $\pi^+$ emitted in a $D^{*+} \rightarrow D^0 \pi^+$ decay and the $e^+$ emitted in the subsequent $D^0 \rightarrow Xe^+\nu$ decay, we have measured the branching fraction for the inclusive semi-electronic decay of the $D^0$ meson to be: {\cal B}(D^0 \rightarrow X e^+ \nu) = [6.64 \pm 0.18 (stat.) \pm 0.29 (syst.)] \%. The result is based on 1.7 fb$^{-1}$ of $e^+e^-$ collisions recorded by the CLEO II detector located at the Cornell Electron Storage Ring (CESR). Combining the analysis presented in this paper with previous CLEO results we find, \frac{{\cal B} (D^0 \rightarrow X e^+ \nu)} {{\cal B} (D^0 \rightarrow K^- \pi^+)} = 1.684 \pm 0.056 (stat.) \pm 0.093(syst.) and \frac{{\cal B}(D\rightarrow K^-e^+\nu)} {{\cal B}(D\rightarrow Xe^+\nu)} = 0.581 \pm 0.023 (stat.) \pm 0.028(syst.). The difference between the inclusive rate and the sum of the measured exclusive branching fractions (measured at CLEO and other experiments) is $(3.3 \pm 7.2) \%$ of the inclusive rate.Comment: Latex file, 33pages, 4 figures Submitted to PR

Precision Measurement of the Ds∗+−Ds+D_s^{*+}- D_s^+ Mass Difference

We have measured the vector-pseudoscalar mass splitting $M(D_s^{*+})-M(D_s^+) = 144.22\pm 0.47\pm 0.37 MeV$, significantly more precise than the previous world average. We minimize the systematic errors by also measuring the vector-pseudoscalar mass difference $M(D^{*0})-M(D^0)$ using the radiative decay $D^{*0}\rightarrow D^0\gamma$, obtaining $[M(D_s^{*+})-M(D_s^+)]-[M(D^{*0})-M(D^0)] = 2.09\pm 0.47\pm 0.37 MeV$. This is then combined with our previous high-precision measurement of $M(D^{*0})-M(D^0)$, which used the decay $D^{*0}\rightarrow D^0\pi^0$. We also measure the mass difference $M(D_s^+)-M(D^+)=99.5\pm 0.6\pm 0.3$ MeV, using the $\phi\pi^+$ decay modes of the $D_s^+$ and $D^+$ mesons.Comment: 18 pages uuencoded compressed postscript (process with uudecode then gunzip). hardcopies with figures can be obtained by sending mail to: [email protected]

Observation of a New Charmed Strange Meson

Using the CLEO-II detector, we have obtained evidence for a new meson decaying to $D^0 K^+$. Its mass is $2573.2^{+1.7}_{-1.6}\pm 0.8\pm 0.5$ {}~MeV/$c^2$ and its width is $16^{+5}_{-4}\pm 3$~MeV/$c^2$. Although we do not establish its spin and parity, the new meson is consistent with predictions for an $L=1$, $S=1$, $J_P=2^+$ charmed strange state.Comment: 9 pages uuencoded compressed postscript (process with uudecode then gunzip). hardcopies with figures can be obtained by sending mail to: [email protected]

Measurements of the Ratios B(Ds+→ηℓ+ν)/B(Ds+→ϕℓ+ν){\cal B}(D_s^+\to \eta\ell^+\nu)/{\cal B}(D_s^+\to \phi\ell^+\nu) and B(Ds+→η′ℓ+ν)/B(Ds+→ϕℓ+ν){\cal B}(D_s^+\to \eta'\ell^+\nu)/{\cal B}(D_s^+\to \phi\ell^+\nu)

Using the CLEO~II detector we measure ${\cal B}(D_s^+\to \eta e^+\nu)/{\cal B}(D_s^+\to \phi e^+\nu) =1.24\pm0.12\pm0.15$, ${\cal B}(D_s^+\to \eta' e^+\nu)/{\cal B}(D_s^+\to \phi e^+\nu) =0.43\pm0.11\pm0.07$ and ${\cal B}(D_s^+\to \eta' e^+\nu)/{\cal B}(D_s^+\to \eta e^+\nu) =0.35\pm0.09\pm0.07$. We find the vector to pseudoscalar ratio, ${\cal B}(D_s^+\to \phi e^+\nu)/{\cal B}(D_s^+\to (\eta+\eta') e^+\nu) =0.60\pm0.06\pm0.06$, which is similar to the ratio found in non strange $D$ decays.Comment: 11 page uuencoded postscript file, postscript file also available through http://w4.lns.cornell.edu/public/CLN

Semileptonic Branching Fraction of Charged and Neutral B Mesons

An examination of leptons in ${\Upsilon (4S)}$ events tagged by reconstructed $B$ decays yields semileptonic branching fractions of $b_-=(10.1 \pm 1.8\pm 1.4)\%$ for charged and $b_0=(10.9 \pm 0.7\pm 1.1)\%$ for neutral $B$ mesons. This is the first measurement for charged $B$. Assuming equality of the charged and neutral semileptonic widths, the ratio $b_-/b_0=0.93 \pm 0.18 \pm 0.12$ is equivalent to the ratio of lifetimes. A postscript version is available through World-Wide-Web in http://w4.lns.cornell.edu/public/CLNS/1994Comment: 9 pages (in REVTEX format) Preprint CLNS94-1286, CLEO 94-1

Search for Exclusive Charmless Hadronic B Decays

We have searched for two-body charmless hadronic decays of $B$ mesons. Final states include $\pi\pi$, $K \pi$, and $KK$ with both charged and neutral kaons and pions; $\pi\rho$, $K \rho$, and $K^*\pi$; and $K\phi$, $K^*\phi$, and $\phi\phi$. The data used in this analysis consist of 2.6~million $B\bar{B}$~pairs produced at the $\Upsilon(4S)$ taken with the CLEO-II detector at the Cornell Electron Storage Ring (CESR). We measure the branching fraction of the sum of $B^0 \rightarrow \pi^+\pi^-$ and $B^0 \rightarrow K^+\pi^-$ to be $(1.8^{+0.6+0.2}_{-0.5-0.3}\pm0.2) \times 10^{-5}$. In addition, we place upper limits on individual branching fractions in the range from $10^{-4}$ to $10^{-6}$.Comment: 33 page LATEX file, uses REVTEX and psfig, 14 figures in a separate uuencoded postscript file, postscript version also available through http://w4.lns.cornell.edu/public/CLN

Production and Decay of D_1(2420)^0 and D_2^*(2460)^0

We have investigated $D^{+}\pi^{-}$ and $D^{*+}\pi^{-}$ final states and observed the two established $L=1$ charmed mesons, the $D_1(2420)^0$ with mass $2421^{+1+2}_{-2-2}$ MeV/c$^{2}$ and width $20^{+6+3}_{-5-3}$ MeV/c$^{2}$ and the $D_2^*(2460)^0$ with mass $2465 \pm 3 \pm 3$ MeV/c$^{2}$ and width $28^{+8+6}_{-7-6}$ MeV/c$^{2}$. Properties of these final states, including their decay angular distributions and spin-parity assignments, have been studied. We identify these two mesons as the $j_{light}=3/2$ doublet predicted by HQET. We also obtain constraints on {\footnotesize $\Gamma_S/(\Gamma_S + \Gamma_D)$} as a function of the cosine of the relative phase of the two amplitudes in the $D_1(2420)^0$ decay.Comment: 15 pages in REVTEX format. hardcopies with figures can be obtained by sending mail to: [email protected]

Observation of the Ξc+\Xi_c^+ Charmed Baryon Decays to Σ+K−π+\Sigma^+ K^-\pi^+, Σ+Kˉ∗0\Sigma^+ \bar{K}^{*0}, and ΛK−π+π+\Lambda K^-\pi^+\pi^+

We have observed two new decay modes of the charmed baryon $\Xi_c^+$ into $\Sigma^+ K^-\pi^+$ and $\Sigma^+ \bar{K}^{*0}$ using data collected with the CLEO II detector. We also present the first measurement of the branching fraction for the previously observed decay mode $\Xi_c^+\to\Lambda K^-\pi^+\pi^+$. The branching fractions for these three modes relative to $\Xi_c^+\to\Xi^-\pi^+\pi^+$ are measured to be $1.18 \pm 0.26 \pm 0.17$, $0.92 \pm 0.27 \pm 0.14$, and $0.58 \pm 0.16 \pm 0.07$, respectively.Comment: 12 page uuencoded postscript file, postscript file also available through http://w4.lns.cornell.edu/public/CLN

Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer

Introduction: In developed countries, ovarian cancer is the fourth most common cancer in women. Due to the nonspecific symptomatology associated with the disease many patients with ovarian cancer are diagnosed late, which leads to significantly poorer prognosis. Apart from surgery and radiotherapy, a substantial number of ovarian cancer patients will undergo chemotherapy and platinum based agents are the mainstream first-line therapy for this disease. Despite the initial efficacy of these therapies, many women relapse; therefore, strategies for second-line therapies are required. Regulation of DNA transcription is crucial for tumour progression, metastasis and chemoresistance which offers potential for novel drug targets. Methods: We have reviewed the existing literature on the role of histone deacetylases, nuclear enzymes regulating gene transcription. Results and conclusion: Analysis of available data suggests that a signifant proportion of drug resistance stems from abberant gene expression, therefore HDAC inhibitors are amongst the most promising therapeutic targets for cancer treatment. Together with genetic testing, they may have a potential to serve as base for patient-adapted therapies